Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Is there an increased risk of developing de novo inflammatory bowel disease while under treatment with anti-TNF-alpha for other chronic inflammatory or immune-mediated diseases?
Do non-aspirin nonsteroidal anti-inflammatory drugs offer protection against colorectal cancer? This study examined the chemoprotective effect of both COX-2 selective and nonselective NSAIDs.
This review explores controversies surrounding the potential impact of DAA therapy on the incidence and prognosis of hepatocellular carcinoma in patients with advanced liver disease.
This study investigated the mechanisms by which altered gut microbiota impact the development and progression of NAFLD. Might microbiota-targeting therapies be beneficial?
Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than IBD.
Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.
Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects.
